Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Lymphoma 23Burkitt Lymphoma 22Multiple Myeloma 20Lymphoma, Non-Hodgkin 17Leukemia, Myeloid, Acute 16Lymphoma, Follicular 15Myelodysplastic Syndromes 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell 13Leukemia, Biphenotypic, Acute 13Lymphoma, T-Cell 9Hodgkin Disease 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Neuroblastoma 7Lymphoma, B-Cell, Marginal Zone 7Glioma 7Wilms Tumor 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Central Nervous System Neoplasms 6Rhabdoid Tumor 5Primary Myelofibrosis 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Myeloproliferative Disorders 5Mycosis Fungoides 5

Interventions

Peripheral Blood Stem Cell Transplantation 39fludarabine phosphate 36Cyclophosphamide 31Mycophenolic Acid 28Cyclosporine 25Whole-Body Irradiation 24Tacrolimus 22Busulfan 18Antilymphocyte Serum 18Radiotherapy 16Methotrexate 16Flow Cytometry 14Filgrastim 14Etoposide 13Methylprednisolone 10Lenalidomide 10Bortezomib 10Vorinostat 9Melphalan 9mogamulizumab 8Therapeutics 8Rituximab 8Psychiatric Rehabilitation 8Polymerase Chain Reaction 8Gemcitabine 8Cord Blood Stem Cell Transplantation 7Bexarotene 7pembrolizumab 6Alemtuzumab 6tanespimycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sezary Syndrome × Specimen Handling × Lymphoid × Clear all
NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

NCT04652960 2026-05-13

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

National Cancer Institute (NCI)

Phase 1 Active not recruiting
38 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

National Cancer Institute (NCI)

Phase 1/2 Terminated
8 enrolled 8 charts
Lymphoid

Mycosis Fungoides, Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡